
Eyenuk
Eyenuk, Inc.: A global leader in AI-powered eye disease detection, based in Woodland Hills, US.
- 30
- Company
- Woodland Hills, CA, USUnited States

Eyenuk, Inc.: A global leader in AI-powered eye disease detection, based in Woodland Hills, US.
eyenuk.comCrawled Oct 16, 2026
Eyenuk offers AI triage solutions to identify and prioritize patients who require urgent specialist eye care.
Eyenuk's AI eye screening solution, EyeArt, provides rapid, accurate, and autonomous disease detection without the need for an eye specialist.
The page presents clinical evidence on Eyenuk's EyeArt AI system, including peer-reviewed evidence of diagnostic accuracy and autonomous eye screening safety.
Expert insights on autonomous AI retinal screening, diabetic retinopathy detection, health equity, and FDA-cleared diagnostic systems for primary care.
The page describes a clinical study comparing Eyenuk's EyeArt AI system with ophthalmologists' dilated exams for detecting more than mild diabetic retinopathy.
Analyze the diagnostic accuracy and cost-effectiveness of Eyenuk's automated diabetic retinopathy image assessment software compared against human graders.
Eyenuk AI technology has been selected for diabetic eye testing in Vietnam, supported globally by the renowned Fred Hollows Foundation.
Eyenuk appoints Mads Dall as Chairman of the Board and Gaurav Agarwal as Chief Executive Officer to lead the AI digital health company.
Eyenuk has officially been granted CE Marking for EyeArt, allowing the autonomous AI eye screening system to be utilized across Europe.
Eyenuk joins the Population Health Alliance, paving the way for autonomous AI to actively improve diabetic complications and patient care.
EyeArt by Eyenuk is an autonomous, FDA-cleared AI for diabetic retinopathy screening and disease detection at the point of care.
Eyenuk's Privacy Policy explains how the company protects personal information and addresses GDPR, HIPAA, and cybersecurity compliance for its AI solutions.
Eyenuk deploys autonomous AI eye screening technology for Norway’s national health system to combat ophthalmologist shortages. The system supports early detection of eye conditions, reducing preventable vision loss. This marks the first national adoption of such autonomous AI screening in healthcare.
Sep 2025GlobeNewswireNews article
Eyenuk names Mads Dall as its new Chairman of the Board and promotes Gaurav Agarwal to Chief Executive Officer. The company specializes in AI-driven digital health solutions with a focus on real-world applications. These leadership changes aim to strengthen the company’s strategic direction and operational growth.
Jan 2025GlobeNewswireNews article
Eyenuk secures FDA clearance for a new camera designed to autonomously detect diabetic retinopathy. The device integrates Real-Time Quality Feedback to enhance retinal image quality and minimize the need for pupil dilation, broadening screening options for primary care clinics serving diabetic patients.
Jun 2023ophthalmologytimes.comNews article
Eyenuk raises $26 million in Series A funding to expand its AI-powered eye-screening technology globally. The company specializes in real-world applications of AI for digital health, aiming to improve accessibility to eye care solutions. The funding will support scaling operations and further development of its diagnostic tools.
Oct 2022PR NewswireNews article